... does not elicit significant clinical outcomes in most patients.
“The expression level of EGFR in cancer tissues is correlated with prognosis, but not with responsiveness to EGFR tyrosine kinase ...
... cancer patients with a mutation in the BRAF gene do not respond to anti-EGFR therapy with cetuximab and panitumumab. The finding could help doctors better identify which patients are likely to ...
... and Gynaecology Service report that women with vulvar carcinoma whose tumours have extra copies of the epidermal growth factor receptor (EGFR) gene are at increased risk of dying from their cancer...
... inhibits the epidermal growth factor receptor (EGFR). It is widely used to treat colorectal cancer and head ... antigen binding sites of two different EGFR-specific antibodies: 425 (matuzumab) and C225 ...
... HER2) are involved in the carcinogenesis of many malignancies. Therapeutic molecules targeting EGFR and HER2 have been successfully used for the treatment of colorectal, breast, lung and head and neck ...
... addition, the researchers found that patients whose tumor expressed a marker called EGFR had worse outcomes.
“The combination of markers was an important indicator. Patients whose tumors expressed ...
... Also, EGFR over-expression has been associated with endocrine resistance. If there's a double blockage of the EGFR and the estrogen receptor, you may achieve better control of the disease."
The Phase ...
... of resistance,” says Sequist. “We think these results will also apply to other effective EGFR inhibitors, and we hope they can be duplicated for other types of cancer that involve these mutations. ...
... known as the epidermal growth factor receptor (EGFR) or a peptide hormone called epidermal growth ... cancer drugs that fight tumors driven by EGFR-like receptors, such as Herceptin, Erbitux and Tarceva ...
Drugs that target members of the EGFR family of proteins have proven effective for the treatment of certain types of cancer, including breast cancer. However, in a large number of patients for whom ...
... cancerous growth induced by various cancer-causing proteins, such as Her2 and EGFR. With that knowledge in hand, the researchers, in collaboration with pharmaceutical companies, are developing ...
... both discovered that mutations in a protein called EGFR determine whether NSCLC tumors respond ... blood samples from 27 patients – 23 who had EGFR mutations and 4 who did not – and CTCs were identified ...
... HER2 and the epidermal growth factor receptor (EGFR), is able to cross the blood–brain barrier ... molecular therapeutic is lapatinib, a dual inhibitor of EGFR and HER2 kinases," the authors write
Contact ...
... , Thomas H. Hostetter, MD, of Albert Einstein College of Medicine believes that expanding the use of eGFR will allow CKD to be diagnosed and treated at an earlier stage. Richard J. Glasscck, MD of the ...
... they found that IKKα turns down a cellular signaling loop that activates EGFR and other growth factors previously found to regulate keratinocyte proliferation and differentiation.
Another experiment ...
